Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 May 21;8(10):e012523.
doi: 10.1161/JAHA.119.012523.

Is Paclitaxel Causing Mortality During Lower-Extremity Revascularization?

Rajesh V Swaminathan  1 , W Schuyler Jones  1 , Manesh R Patel  1
Affiliations
Comment

Is Paclitaxel Causing Mortality During Lower-Extremity Revascularization?

Rajesh V Swaminathan et al. J Am Heart Assoc. .
No abstract available

Keywords: Drug‐coated balloon; drug‐eluting stent; mortality; paclitaxel.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Paclitaxel‐coated devices as the focus of various types of clinical outcome data. Initial randomized controlled trials of these devices were focused on efficacy end points and not powered for safety events. A safety alert signal from a recent systematic review and meta‐analysis has led to analyses of larger registries and Centers for Medicare and Medicaid Services (CMS) data. Further studies at the patient level and with longer‐term follow‐up are pending. This highlights the future importance of capturing longitudinal clinical outcome data via a pragmatic approach. DCB indicates drug‐coated balloon; DES, drug‐eluting stent.
See this image and copyright information in PMC

Comment on

References

    1. Hunink MG, Donaldson MC, Meyerovitz MF, Polak JF, Whittemore AD, Kandarpa K, Grassi CJ, Aruny J, Harrington DP, Mannick JA. Risks and benefits of femoropopliteal percutaneous balloon angioplasty. J Vasc Surg. 1993;17:183–192. - PubMed
    1. Vardi M, Novack V, Pencina MJ, Doros G, Burke DA, Elmariah S, Cutlip DE, Mauri L, Yeh RW. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta‐analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014;83:975–983. - PubMed
    1. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators . Paclitaxel‐eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve‐month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504. - PubMed
    1. Rosenfield K, Jaff MR, White CJ, Rocha‐Singh K, Mena‐Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller‐Hülsbeck S, Nehler MR, Benenati JF, Scheinert D; LEVANT 2 Investigators . Trial of a paclitaxel‐coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153. - PubMed
    1. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR; for the IN.PACT Trial Investigators . Drug‐coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12‐month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502. - PMC - PubMed

LinkOut - more resources